Breakthrough Therapies Act
Summary
Breakthrough Therapies Act This bill provides for the classification of drugs or other substances that are part of approved breakthrough therapies as schedule II controlled substances under the Controlled Substances Act. It also provides for expedited controlled substance registrations through the Drug Enforcement Administration for researchers whose work involves investigational drugs.
Bill status
in committee
1 of 4 stages cleared
Introduction
Nov 2022
Committee Review
Floor Vote
President
Introduced Nov 17, 2022
Last action Nov 17, 2022
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
2
Key actions
0
Committee
1
Nov 17, 2022
Committee
Read twice and referred to the Committee on the Judiciary.
upper
Nov 17, 2022
Introduced
Introduced in Senate
upper
1 primary · 1 co-sponsor
Sponsors
Ask Maddy
·
AI policy assistant
Ask Maddy about S 5123
Scope: US
Hi! I can help you understand S 5123. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline